A detailed history of Raymond James & Associates transactions in Cybin Inc. stock. As of the latest transaction made, Raymond James & Associates holds 23,153 shares of CYBN stock, worth $222,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,153
Previous 22,903 1.09%
Holding current value
$222,268
Previous $9,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$0.26 - $0.46 $65 - $115
250 Added 1.09%
23,153 $6,000
Q1 2024

Apr 22, 2024

BUY
$0.3 - $0.46 $6,870 - $10,535
22,903 New
22,903 $9,000

Others Institutions Holding CYBN

About CYBIN INC.


  • Ticker CYBN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 166,120,000
  • Market Cap $1.59B
  • Description
  • Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...
More about CYBN
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.